|
rs1001179
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analyses revealed a significant association between the rs1001179 polymorphism and prostate cancer in all models except the homozygote comparison.
|
27449288 |
2016 |
|
rs1004072779
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Significant association of TMPRSS2-ERG fusion-positive PCa was found with rare variants in the genes for POLI [variant F532S: P = 0.0011; odds ratios (OR), 4.62; 95% confidence interval (95% CI), 1.84-11.56] and ESCO1 (variant N191S: P = 0.0034; OR, 4.27; 95% CI, 1.62-11.28).
|
19861517 |
2009 |
|
rs10046
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The combination of the TTTA long repeats and the minor alleles of rs10046 in CYP19A1 and rs2077647 in ESR-alpha was a high risk for prostate cancer despite greater than or equal to 60 mg isoflavones/day.
|
19952760 |
2010 |
|
rs10069690
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The T allele of the intron 4 SNP (rs10069690) was found to be significantly associated with a decreased risk for an aggressive form of PCa (OR=0.76; 95% CI: 0.59-0.97; P=0.030).
|
25738283 |
2015 |
|
rs1012477
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our results showed that at least one SNP in nine core circadian genes (rs885747 and rs2289591 in PER1; rs7602358 in PER2; rs1012477 in PER3; rs1534891 in CSNK1E; rs12315175 in CRY1; rs2292912 in CRY2; rs7950226 in ARNTL; rs11133373 in CLOCK; and rs1369481, rs895521, and rs17024926 in NPAS2) was significantly associated with susceptibility to prostate cancer (either overall risk or risk of aggressive disease), and the risk estimate for four SNPs in three genes (rs885747 and rs2289591 in PER1, rs1012477 in PER3, and rs11133373 in CLOCK) varied by disease aggressiveness.
|
19934327 |
2009 |
|
rs10165970
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10175368
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results demonstrate smoking and alcohol consumption to modify the risks of CYP1B1 polymorphisms for prostate cancer which may be through rs10175368, and this is of importance in understanding their role in the pathogenesis and as a biomarker for this disease.
|
30133114 |
2018 |
|
rs1024611
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to analyze the frequencies of CCL2 (I/D, rs3917887), -2518 (A > G, rs1024611), and CCR2 (G > A, rs1799864) polymorphisms for prostate cancer (PCa) risk.
|
25266801 |
2015 |
|
rs1034528
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the single-locus analysis, we found a significantly increased risk of PCa associated with mTOR rs2536 CT/CC and rs1034528 CG/CC genotypes [adjusted OR = 1.42 (1.13-1.78), P = 0.003 and 1.29 (1.07-1.55), P = 0.007), respectively], compared with their common homozygous genotypes, whereas mTOR rs2295080 GT/GG genotypes were associated with a decreased risk of PCa [adjusted OR = 0.76 (0.64-0.92), P = 0.003], compared with wild-type TT genotypes.
|
23940798 |
2013 |
|
rs1041258260
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aim of the present study was to analyze the effect of XPG Asp 1104His and XRCC1 Arg309Gln polymorphisms on risk of prostate cancer in north Indian population.
|
21670956 |
2012 |
|
rs1042489
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aim of this study was to investigate the possible association of c.-31G>C (rs9904341), c.454G>A (rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of <i>survivin</i> gene with prostate cancer risk and provide some justification using <i>in silico</i> analysis.
|
30034311 |
2018 |
|
rs1042636
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Because serum calcium levels are influenced by the calcium-sensing receptor (CaSR), we examined prostate cancer in African-American men in relation to three single nucleotide polymorphisms (SNPs) in the CaSR gene, A986S, R990G and Q1011E.
|
20364112 |
2010 |
|
rs10426628
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
According to a multivariate analysis, CYP1B1 (rs1800440), COMT (rs16982844), and SULT2B1 (rs12460535, rs2665582, rs10426628) were significantly associated with prostate cancer progression and hormone levels.
|
24682418 |
2014 |
|
rs10432782
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two variants in SOD2 were significantly associated with the risk of aggressive prostate cancer (rs17884057, odds ratio 0.83, 95% confidence interval 0.70-0.99; and rs4816407, 1.27, 1.02-1.57); men with A alleles at rs2842958 in SOD2 had lower plasma selenium levels (median 116 vs 121.8 µg/L, P= 0.03); and the association between plasma selenium levels and risk of aggressive prostate cancer was modified by SOD1 (rs10432782) and SOD2 (rs2758330).
|
20477822 |
2011 |
|
rs10459592
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haplotype analysis showed that the T-A-G haplotype (corresponding to rs2470152-rs10459592-rs4775936) increased the risk of prostate cancer, while the C-C-A haplotype decreased the risk.
|
24803183 |
2015 |
|
rs1046040
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haplotype analysis proposed that rs3787016 T/rs1046040 C significantly increased the risk of PCa compared to C/C (p = 0.037).
|
30587086 |
2019 |
|
rs1047768
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a hospital-based case-control study of 1,004 PCa cases and 1,055 cancer-free controls, we genotyped eight potentially functional single nucleotide polymorphisms (SNPs) of NER genes (i.e., XPC, rs2228001 T>G and rs1870134 G>C; XPD, rs13181 T>G and rs238406 G>T; XPG, rs1047768 T>C, rs751402 C>T, and rs17655 G>C; and XPF, rs2276464 G>C) and assessed their associations with risk of PCa by using logistic regression analysis.
|
27974699 |
2017 |
|
rs1047840
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our results suggest that CDH1 -160C/A and Exo1 K589E polymorphisms are associated with increased susceptibility to prostate cancer in Bangladeshi population.
|
30880589 |
2019 |
|
rs10483813
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aim of the present study was to evaluate the relationship between prostate cancer risk and the presence of single nucleotide polymorphisms (SNPs) in the genes involved in HRR, that is, RAD51 (rs1801320 and rs1801321), RAD51B (rs10483813 and rs3784099), XRCC2 (rs3218536), and XRCC3 (rs861539).
|
26339569 |
2015 |
|
rs1049216
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Specifically, the results of study seem to hint at a higher risk of PCa in smokers of up to 20 pack-years (PY) and carriers of both the CASP3-rs1049216 GG genotype and the G allele (OR = 3.61, p = 0.044; OR = 1.71; p = 0.018).
|
30176316 |
2018 |
|
rs10505346
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Recently, TNFRSF11B rs10505346 has been implicated in PCa risk in the Cancer Genetic Markers of Susceptibility genomewide association study.
|
20204532 |
2010 |
|
rs10505474
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
rs10505474 and rs7837328 at 8q24 cumulatively confer risk of prostate cancer in Northern Han Chinese.
|
24815458 |
2014 |
|
rs10519097
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs1052576
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP9 (rs1052576) C allele was decreasing the risk for pathological stage of patients with prostate cancer and also CT genotype had positive impact on pathological stage of patients with prostate cancer.
|
28358701 |
2017 |
|
rs1057519912
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
MED12 mutations in exon 26, resulting in a substitution of leucine 1224 to phenylalanine (L1224F), have been recurrently observed in prostate cancer.
|
26383637 |
2016 |